Grote L, Heitmann J, Köhler U, Ploch T, Penzel T, Peter J H
Medizinische Poliklinik, Klinikum der Philipps-Universität Marburg, Germany.
Blood Press. 1997 Jul;6(4):235-41. doi: 10.3109/08037059709062075.
We investigated the efficacy of an Angiotensin Converting Enzyme [ACE] inhibitor on daytime and night-time blood pressure in 55 male hypertensive patients with moderately severe to severe obstructive sleep apnea. We resolved to determine if treatment oriented towards the reduction of hypertension would be successful, despite persistent repetitive hypoxemia and sleep-disordered breathing. The study was a randomized, double-blind, single daily dose, placebo-controlled protocol, with 8 days drug intake (placebo or 2.5 mg Cilazapril) and monitoring on the final day of drug administration. Subjects underwent continuous 24-h arterial blood pressure monitoring during baseline and treatment conditions. Polysomnography was performed at night during the 24-h arterial monitoring period. Cilazapril (2.5 mg) lowered systolic, diastolic and mean blood pressure, despite persistence of repetitive obstructive apneas during sleep and the associated repetitive hypoxemia. The lowering of blood pressure occurred without a significant change in heart rate, and was noted during nocturnal sleep, performance testing and graded exercise.
我们研究了一种血管紧张素转换酶（ACE）抑制剂对55名患有中度至重度阻塞性睡眠呼吸暂停的男性高血压患者日间和夜间血压的疗效。我们决心确定，尽管存在持续性反复低氧血症和睡眠呼吸紊乱，以降低高血压为导向的治疗是否会成功。该研究采用随机、双盲、每日单剂量、安慰剂对照方案，服药8天（安慰剂或2.5毫克西拉普利），并在给药的最后一天进行监测。受试者在基线和治疗条件下接受连续24小时动脉血压监测。在24小时动脉监测期间的夜间进行多导睡眠图检查。尽管睡眠期间持续性反复阻塞性呼吸暂停及相关反复低氧血症持续存在，但西拉普利（2.5毫克）降低了收缩压、舒张压和平均血压。血压降低时心率无显著变化，且在夜间睡眠、性能测试和分级运动期间均有此现象。
